- Jun 06, 2018 Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference
- Jun 03, 2018 Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea
- Jun 03, 2018 Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
- May 31, 2018 New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea
Data provided by Nasdaq. Minimum 15 minutes delayed.